Determine Your Priorities to Finding the Right CDMO

This article is the second part of our “Best Practices in the CDMO Selection Process” series, through which we intend to provide sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the development of their product(s), in conjunction with successfully managing a chosen CDMO to meet the company’s expectations.

Published on:
September 1, 2022

In this article, we will detail the best practices for working with a CDMO to ensure the success of your product development. After having identified the need for engaging a CDMO, the next steps would entail the evaluation of your options. Before looking at a CDMO’s capabilities, it’s important to assess your priorities as the sponsor company.

CDMOs also vary in technological competencies and abilities and it’s important to understand the strengths and limitations of each CDMO in order to select the ones most suitable to match your priorities.
Creating a Target Product Profile or TPP

The foundation for CDMO selection begins with creating a Target Product Profile (TPP). This is an in-depth roadmap of your product—what qualities define it, how it will be administered and what clinical setting it will be used in. The TPP should include:

  • Product description
  • Indications and usage
  • Dosage and administration
  • Dosage forms and strengths
  • Manufacturing technology and process
  • Scale of production
  • Storage condition

The TPP is a living document that evolves alongside the overall product development plan and serves as your company’s guideline throughout the process. It aids in matching priorities to the extent that they are known. We recommend a review of the FDA’s guidance document from March 2007 on writing a TPP for best practices.

Understanding and outlining your Priorities

Before selecting a CDMO for your project or company, you need to define three major factors:

  • Quality
  • Timeline
  • Cost

Quality is of top priority when it comes to manufacturing pharmaceuticals and cannot be compromised at all. Generally, timeline and cost vary inversely, so a decision needs to be made as to your second highest priority. If the timeline is of greater importance, expect to pay more for the requested services. If cash flow is limited and cost is of second priority, you may need to be flexible on the timeline.

Keep in mind that as a sponsor, you may believe that you have a failsafe product; however, when scaled, it may prove otherwise. This can lead to both increased time and cost. CDMOs also vary in technological competencies and abilities and it’s important to understand the strengths and limitations of each CDMO in order to select the ones most suitable to match your priorities.

Once a TPP is in place, begin your evaluation process by developing a list of candidate CDMOs. Create your own list or enlist the assistance of a consulting group with solid expertise to assist in finding suitable candidates.

Creating a like-for-like comparison

Next, draft your Request for Proposal (RFP) using the information contained in your TPP, defining the requested scope of work and associated timeline. A single RFP is needed to describe your project and that RFP can be issued to multiple CDMOs previously identified as suitable candidates for your project. Our recommendation is to send the RFP to 6–8 CDMOs, as not all CDMOs will respond.

CDMOs have business development teams in place, who receive RFPs and draft proposals in response. Allow 3–4 weeks for receipt of proposals, which will be returned to you by the due date specified in your RFP. Since all CDMOs are responding to the same RFP, you can pull similar information from each response proposal into a single spreadsheet to generate a straightforward, like-for-like comparison.

Using this comparison spreadsheet, rank your candidate CDMOs using weighted criteria reflecting your top priorities while also considering risk to quality, timeline and cost. This comparison and knowing what to look for in the right CDMO will help you make the right selection.

If you have decided to outsource your manufacturing and would like to identify the right CDMO for your project, we are here to assist. Our expert team has been helping companies choose the right CDMO for more than a decade — reach out to us to learn how we can support.

Related news

Publications January 18, 2023
The State of Biopharma Funding
We spoke with Joris Pezzini, Executive Vice President of Biopharma, Alira Health, during the J.P. Morgan Healthcare Conference in San Francisco, which brings together investors and(...)
Biopharma Biotech Funding Pharma
Events January 11, 2023
MD&M West 2023
Join our colleague Carlo Stimamiglio for his presentation “MedTech CDMO: Market and M&A Trends in 2023”, as he goes over key takeaways from our upcoming 2023 US MedTech CDMO Report.
CDMO MedTech
Publications December 6, 2022
Review of 2021-22 and 2023 Outlook: Report on the European MedTech CDMO Industry
A return to normalcy has accelerated growth for Europe’s MedTech CDMO industry, but individual companies may be at risk given the increased competitive pressure, logistics disruption,(...)
CDMO MedTech
Events November 30, 2022
Biotech Showcase
We are pleased to attend Biotech Showcase this year, the investor conference for innovators. This will be the 15th edition of the event and it hosts a wide variety of companies, ranging(...)
Biotech Investor Relations Life Sciences
Publications November 10, 2022
How to Choose the Right Analytical Methods
In this article, we focus on the analytical method development around your biologics. Analytical method development is an important component of biologics development and the control(...)
Biotech CDMO Drug Development
News September 27, 2022
AseBio and Alira Health Partner to Foster Market Access for Biotech Startups
Alira Health and AseBio, the Spanish Bioindustry Association, are joining forces to support Spanish biotech companies looking to enter new markets.
Biotech Market Access Startups
Publications September 14, 2022
Critical Quality Attributes for Drug Products
In this article, we will explore the importance of Critical Quality Attributes (CQAs) in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.
Biotech CDMO Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.